Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome of patients aged >or=75 years in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK (SHOCK) trial: do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization?
Dzavik V, Sleeper LA, Picard MH, Sanborn TA, Lowe AM, Gin K, Saucedo J, Webb JG, Menon V, Slater JN, Hochman JS; SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK Investigators. Dzavik V, et al. Among authors: hochman js. Am Heart J. 2005 Jun;149(6):1128-34. doi: 10.1016/j.ahj.2005.03.045. Am Heart J. 2005. PMID: 15976798 Clinical Trial.
Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial.
Webb JG, Lowe AM, Sanborn TA, White HD, Sleeper LA, Carere RG, Buller CE, Wong SC, Boland J, Dzavik V, Porway M, Pate G, Bergman G, Hochman JS; SHOCK Investigators. Webb JG, et al. Among authors: hochman js. J Am Coll Cardiol. 2003 Oct 15;42(8):1380-6. doi: 10.1016/s0735-1097(03)01050-7. J Am Coll Cardiol. 2003. PMID: 14563578 Free article. Clinical Trial.
Electrocardiographic findings in cardiogenic shock, risk prediction, and the effects of emergency revascularization: results from the SHOCK trial.
White HD, Palmeri ST, Sleeper LA, French JK, Wong CK, Lowe AM, Crapo JW, Koller PT, Baran KW, Boland JL, Hochman JS, Wagner GS; SHOCK Trial Investigators. White HD, et al. Among authors: hochman js. Am Heart J. 2004 Nov;148(5):810-7. doi: 10.1016/j.ahj.2004.05.012. Am Heart J. 2004. PMID: 15523311 Clinical Trial.
Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study.
Dzavík V, Cotter G, Reynolds HR, Alexander JH, Ramanathan K, Stebbins AL, Hathaway D, Farkouh ME, Ohman EM, Baran DA, Prondzinsky R, Panza JA, Cantor WJ, Vered Z, Buller CE, Kleiman NS, Webb JG, Holmes DR, Parrillo JE, Hazen SL, Gross SS, Harrington RA, Hochman JS; SHould we inhibit nitric Oxide synthase in Cardiogenic shocK 2 (SHOCK-2) investigators. Dzavík V, et al. Among authors: hochman js. Eur Heart J. 2007 May;28(9):1109-16. doi: 10.1093/eurheartj/ehm075. Epub 2007 Apr 25. Eur Heart J. 2007. PMID: 17459901 Clinical Trial.
Impact of the New York State Cardiac Surgery and Percutaneous Coronary Intervention Reporting System on the management of patients with acute myocardial infarction complicated by cardiogenic shock.
Apolito RA, Greenberg MA, Menegus MA, Lowe AM, Sleeper LA, Goldberger MH, Remick J, Radford MJ, Hochman JS. Apolito RA, et al. Among authors: hochman js. Am Heart J. 2008 Feb;155(2):267-73. doi: 10.1016/j.ahj.2007.10.013. Epub 2007 Dec 19. Am Heart J. 2008. PMID: 18215596
455 results